Traumatic brain injury (TBI) continues to represent a major source of trauma-related morbidity and mortality in the USA, accounting for nearly one-third of all injury deaths. The growing proportion of elderly patients, many chronically anticoagulated for atrial fibrillation, venous thromboembolism, or prosthetic valves, poses a growing clinical challenge. The study by Kulvatunyou et al provides an important, large-scale contribution to this topic by examining the effect of preinjury anticoagulation (AC) on mortality after isolated TBI. Using data from the ACS-TQIP (American College of Surgeons Trauma Quality Improvement Program) database, the authors performed a propensity score matched analysis of nearly 97 000 patients over age 50, stratified by head injury severity.
Their findings reveal that preinjury AC significantly increases mortality among patients with mild (absolute difference 1.3%) and moderate TBI (7.9%), but not among those with severe injury. This stratified pattern refines earlier literature and supports the concept that AC’s effect is most consequential in potentially survivable injuries, where hemorrhagic progression may determine the outcome. In severe TBI, however, the high baseline mortality likely overshadows the marginal effect of AC.
The use of propensity score matching stratified by injury severity is a strength of this analysis. Limitations remain, most significantly a lack of data on anticoagulant class, dosing, and most importantly, reversal therapy, which is standard of care in many institutions. The study also found no significant difference in neurosurgical intervention rates, suggesting that AC’s deleterious effect may reflect hemorrhagic or systemic complications not amenable to operative management.
These results align with recent meta-analyses that demonstrated heterogeneity in outcomes depending on injury severity and anticoagulant type.1 2 The ongoing shift from vitamin K antagonists to direct oral anticoagulants (DOACs) adds further complexity: while large randomized trials in non-trauma populations show reduced intracranial hemorrhage with DOACs,3 4 trauma-specific studies remain conflicting, some showing worse outcomes,5 others improved survival.6 Future research should integrate physiologic and imaging-based endpoints, such as volumetric hemorrhage progression,7 to clarify mechanisms and guide targeted interventions.
In summary, Kulvatunyou et al offer a critical addition to the evidence base, highlighting that preinjury AC remains a modifiable risk factor influencing mortality in isolated TBI. Their work underscores the need for more research to investigate the effect of anticoagulant type, reversal strategies, and quantitative hemorrhage data to inform precision care for this growing and vulnerable population.
No authors are employees of the US federal government.
Footnotes
Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Patient consent for publication: Not applicable.
Ethics approval: Not applicable.
Provenance and peer review: Commissioned; internally peer reviewed.
References
- 1.Lim XT, Ang E, Lee ZX, Hajibandeh S, Hajibandeh S. Prognostic significance of preinjury anticoagulation in patients with traumatic brain injury: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2021;90:191–201. doi: 10.1097/TA.0000000000002976. [DOI] [PubMed] [Google Scholar]
- 2.Santing JAL, Lee YX, van der Naalt J, van den Brand CL, Jellema K. Mild Traumatic Brain Injury in Elderly Patients Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. J Neurotrauma. 2022;39:458–72. doi: 10.1089/neu.2021.0435. [DOI] [PubMed] [Google Scholar]
- 3.Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. doi: 10.1056/NEJMoa1009638. [DOI] [PubMed] [Google Scholar]
- 4.Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. doi: 10.1056/NEJMoa1107039. [DOI] [PubMed] [Google Scholar]
- 5.Zeeshan M, Jehan F, O’Keeffe T, Khan M, Zakaria ER, Hamidi M, Gries L, Kulvatunyou N, Joseph B. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg. 2018;85:915–20. doi: 10.1097/TA.0000000000001995. [DOI] [PubMed] [Google Scholar]
- 6.Feeney JM, Santone E, DiFiori M, Kis L, Jayaraman V, Montgomery SC. Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: A TQIP study. J Trauma Acute Care Surg. 2016;81:843–8. doi: 10.1097/TA.0000000000001245. [DOI] [PubMed] [Google Scholar]
- 7.Kulvatunyou N, Bauman ZM, Ramirez AD, Cordy B, Sherman WS, Jarrin G, Tompeck A, Dabrowski P, Feinstein A, Keric N. Effect of anticoagulation on isolated traumatic brain injury mortality using TQIP database: a propensity score analysis stratified by head injury severity. Trauma Surg Acute Care Open. 2025;10:e001839. doi: 10.1136/tsaco-2025-001839. [DOI] [PMC free article] [PubMed] [Google Scholar]